Combination antiviral and anti-inflammatory therapy mitigates persistent neurological deficits in mice post SARS-CoV-2 infection
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Post-acute sequelae of COVID-19 (PASC) encompasses persistent neurological disease, including olfactory and cognitive dysfunction. The basis for this dysfunction is poorly understood. Here, we report neurological dysfunction for at least 120 d postinfection in mice infected with a virulent nonneurotropic mouse-adapted SARS-CoV-2. Long after recovery from nasal infection, we observed diminished tyrosine hydroxylase expression in olfactory bulb glomeruli and in substantia nigra. Similar changes were observed in brains of COVID-19 deceased patients. Vulnerability of dopaminergic neurons in these brain areas was accompanied by increased proinflammatory cytokines, and neurobehavioral changes. RNAseq analysis unveiled persistent microglia activation, similar to human neurodegenerative diseases. Treatment with antivirals (nirmatrelvir and molnupiravir) at the time of infection minimally prevented neurological abnormalities, consistent with patient data. In contrast, antivirals plus corticosteroids resulted in nearly complete recovery of neurological function. Remarkably, initiation of combined therapy even three days after infection improved outcomes. Together these results demonstrate that neurological dysfunction in SARS-CoV-2 infected mice resembles human neurodegenerative disease and indicate that minimizing inflammation early after SARS-CoV-2 infection may be critical for decreasing neurological PASC. The requirement for decreasing inflammation soon after infection may also explain why antiviral therapy has had inconsistent effects in patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Combination antiviral and anti-inflammatory therapy mitigates persistent neurological deficits in mice post SARS-CoV-2 infection
- Date Crossref
- 07/01/2026
- Éditeur
- National Academy of Sciences
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Iowa Department of Microbiology and Immunology pays non établi dans la noticeUniversité ou école supérieure
-
University of Minnesota Minnesota Supercomputing Institute pays non établi dans la noticeUniversité ou école supérieure
-
Pittsburgh Supercomputing Center pays non établi dans la noticeStructure de recherche
-
Stowers Institute for Medical Research Department of Cell Biology and Physiology pays non établi dans la noticeOrganisation à but non lucratif
-
Case Western Reserve University Department of Neurosciences pays non établi dans la noticeUniversité ou école supérieure
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Department of Neurology pays non établi dans la noticeInstitution
Department of Microbiology and Immunology — University of Iowa, Minnesota Supercomputing Institute — University of Minnesota et Pittsburgh Supercomputing Center, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.